Clinical observation of Xuebijing Injection on adjunctive therapy for stroke-associated pneumonia
10.7501/j.issn.0253-2670.2013.16.018
- Author:
Jiang-Ying WU
1
Author Information
1. Severe Case Department
- Publication Type:Journal Article
- Keywords:
Adjunctive therapy;
C-reactive protein;
Cerebral infarction;
Stroke-associated pneumonia;
Xuebijing Injection
- From:
Chinese Traditional and Herbal Drugs
2013;44(16):2285-2287
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the clinical therapeutic effect of Xuebijing Injection on stroke-associated pneumonia (SAP). Methods: A total of 42 patients with SAP were randomly divided into two groups. The patients in the two groups were all given regular treatment. Besides the regular treatment, the patients in the Xuebijing group received iv drip of 50 mL Xuebijing Injection twice a day. The course of the treatment was 7 d. Results: The total effective rate in Xuebijing group (90.5%) was significantly higher than that in the control group (66.7%) (P < 0.05). Compared with the control group, the body temperature, respiration, heart rate, white blood cell count, and C-reactive protein of Xuebijing group were obviously improved (P < 0.05). Compared with the control group,the time of defervescence and cough relief in Xuebijing group reduced obviously (P < 0.05). There were no obvious adverse reactions in all patients. Conclusion: Xuebijing Injection has the anti-inflammatory effect and it is a positive adjunctive therapy for the treatment of SAP without obvious adverse reactions.
